Lyka LabsBOM:500259 +0.78%60 Forward Dividend Yield % is 0.00% as of Jul. 12, 2026. GuruFocus rates BOM:500259 with a GF Score™ of 60/100 and a GF Value™ of ₹127.26 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 148 Biotechnology companies, Lyka Labs ranks worse than 675675% on this metric.
As of today (2026-07-12), the Forward Annual Dividend Yield of Lyka Labs is 0.00%.
As of today (2026-07-12), the Trailing Annual Dividend Yield of Lyka Labs is 0.00%.
BOM:500259's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.29 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
BOM:500259 vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Lyka Labs's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Lyka Labs's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Lyka Labs (BOM:500259) has a Forward Dividend Yield % of 0.00% as of Jul. 12, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Lyka Labs and its competitors. According to the industry distribution chart, Lyka Labs ranks #999999 out of 148 companies in the Biotechnology industry.
Is Lyka Labs' Forward Dividend Yield % too high?
Lyka Labs' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Lyka Labs ranks #999999 out of 148 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lyka Labs has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lyka Labs ranks #999999 out of 148 companies for Forward Dividend Yield %. This places Lyka Labs in the lower half of its industry. The industry median Forward Dividend Yield % is 1.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.29, based on 148 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Lyka Labs and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyka Labs's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.26, compared to a current price of ₹72.36 — trading 43.1% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Lyka Labs' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Forward Dividend Yield % is 0.00% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (BOM:500259) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹72.36 is trading 43.1% below its estimated GF Value™ of ₹127.26.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for BOM:500259:
Forward Dividend Yield %: 0.00%
GF Value™: ₹127.26 vs. price of ₹72.36 (43.1% below fair value)
No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
60GF Score
Get the complete analysis for BOM:500259
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500259 has been successfully added to your 